Latest From BioNTech AG
Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish
Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.
Clonal neoantigen immunotherapy developer Achilles Therapeutics tells the Pink Sheet how the regulatory landscape for advanced therapies might not be as tricky as it used to be.
In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.
In an interview at J.P. Morgan, Roche's James Sabry explained why it wants to lead the pack in personalized, neoantigen-directed cellular therapy, after announcing tie-up with Adaptive Biotechnologies.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- BioNTech AG
- Senior Management
Ugur Sahin, MD, CEO
Sierk Poetting, PhD, CFO
Sean Marett, COO
Markus Werner, PhD, VP, Bus. Dev.
- Contact Info
Phone: 6131 9084 0
An der Goldgrube 12
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.